ArticleBreast care (Basel, Switzerland)2012
Radionuclide Therapy of Bone Metastases.
Article in Breast care (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 61 citations in OpenAlex.
- (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study.European journal of nuclear medicine and molecular imaging · 2015Trial
- [Pharmaceutics · 2026Article
- Evaluation ofInternational journal of molecular sciences · 2025Article
- Advanced targeted microsphere embolization for arteriovenous malformations: state-of-the-art and future directions.Neuroradiology · 2025Review
- The current role of nuclear medicine in breast cancer.The British journal of radiology · 2023Review
- A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.Radiology. Imaging cancer · 2023Review
- A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors.Anesthesiology and pain medicine · 2022Review
- A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.International journal of cancer · 2020Observational
- Bone metastases: a comprehensive review of the literature.Molecular biology reports · 2020Review
- Targeted Nanomedicine to Treat Bone Metastasis.Pharmaceutics · 2018Review
- An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.Nature reviews. Urology · 2018Review
- Targeted α Therapies for the Treatment of Bone Metastases.International journal of molecular sciences · 2017Review
- Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism withBMJ case reports · 2017Article
- Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.Journal of applied clinical medical physics · 2016Article
- Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Review
- Minimally invasive local treatments for bone and pulmonary metastases.Minimally invasive surgery · 2014Review
- Bone Metastasis in Breast Cancer.Breast care (Basel, Switzerland) · 2012Article
- Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma.World journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The skeleton is a potential metastatic target of many malignant tumors. Up to 85% of prostate and breast cancer patients may develop bone metastases causing severe pain syndromes in many of them. In patients suffering from multilocular, mainly osteoblastic lesions and pain syndrome, radionuclide therapy is recommended for pain palliation. Low-energy beta-emitting radionuclides ((153)samarium-ethylenediaminetetrameth-ylenephosphonate (EDTMP) and (89)strontium) deliver high radiation doses to bone metastases and micrometastases in the bone marrow, but only negligible doses to the hematopoietic marrow. The response rate regarding pain syndrome is about 75%; about 25% of the patients may even become pain free. The therapy is repeatable, depending on cell counts. Concomitant treatment with modern bisphosphonates does not interfere with the treatment effects. Clinical trials using a new, not yet approved nuclide ((223)Radium) and/or combinations of chemotherapy and radionuclides are aiming at a more curative approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.